Author

Elaine E Wang

Observed name: Elaine E. Wang

Observed institutions: Cornell University, Seres Therapeutics (United States)

OpenAlex ID: A5024244266

Canadian Association for Immunization Research and Evaluation (CAIRE) Guidelines for Industry Sponsored Clinical Trial and Epidemiology Contract Research

2005 · Scott A. Halperin, David Scheifele, et al. · Human Vaccines · 10

Induction of TRPV1 desensitization by a biased receptor agonist

2011 · Elaine E. Wang, Hui Li, et al. · Channels · 4

694 Durability of the Clinical Response to Ser-109, an Investigational Oral Microbiome Therapeutic, in a Phase 3 Open-label Trial (ecospor Iv) in Patients With Recurrent Clostridioides Difficile Infection

2023 · Edward S. Huang, Bret Lashner, et al. · Gastroenterology · 3

S133 An Open-Label Study (ECOSPOR IV) to Evaluate the Safety, Efficacy and Durability of SER-109, an Investigational Oral Microbiome Therapeutic, in Adults With Recurrent Clostridioides difficile Infection (rCDI)

2022 · Sahil Khanna, Paul Feuerstadt, et al. · The American Journal of Gastroenterology · 3

639. Time to Recurrence of Clostridioides difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic

2021 · Thomas J Louie, Matthew Sims, et al. · Open Forum Infectious Diseases · 3

Fr572 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION

2021 · Louis Korman, Bret Lashner, et al. · Gastroenterology · 3

634. Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence

2021 · Stuart H Cohen, Thomas J Louie, et al. · Open Forum Infectious Diseases · 1

Su1873 RESULTS FROM AN OPEN-LABEL STUDY (ECOSPOR IV) TO EVALUATE THE SAFETY AND EFFICACY OF SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (RCDI): A SUBGROUP ANALYSIS

2023 · Darrell S. Pardi, Caterina Oneto, et al. · Gastroenterology

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial

2021 · Elizabeth Hohmann, Paul Feuerstadt, et al. · Open Forum Infectious Diseases

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials

2021 · Matthew Sims, Sahil Khanna, et al. · Open Forum Infectious Diseases

Childhood Obesity: A National Emergency

2016 · Elaine E Wang · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)

Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease

2004 · Elaine E Wang · Archives of Disease in Childhood Education & Practice

Works count: 16

Citation count: 31

H-index: 3

I10-index: 1